Get the Stockscreener App
3.71
0.54%
+0.02
Pre-market:
3.66
-0.05
-1.35%
MaxCyte Inc stock is currently priced at $3.71, with a 24-hour trading volume of 337.42K.
It has seen a +0.54% increased in the last 24 hours and a -14.52% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.68 pivot point. If it approaches the $3.76 resistance level, significant changes may occur.
Previous Close:
$3.69
Open:
$3.67
24h Volume:
337.42K
Market Cap:
$386.32M
Revenue:
$41.29M
Net Income/Loss:
$-37.92M
P/E Ratio:
-11.59
EPS:
-0.32
Net Cash Flow:
$-25.39M
1W Performance:
-6.08%
1M Performance:
-14.52%
6M Performance:
+25.34%
1Y Performance:
-20.04%
1D Range:
$3.585
$3.74
52W Range:
$2.45
$5.545
MaxCyte Inc Stock (MXCT) Company Profile
Name
MaxCyte Inc
Sector
Industry
Phone
301 944 1700
Address
22 Firstfield Road, Suite 110, Gaithersburg
MaxCyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
MaxCyte Inc Stock (MXCT) Latest News
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
GlobeNewswire Inc.
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
GlobeNewswire Inc.
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Benzinga
MaxCyte Inc Stock (MXCT) Financials Data
MaxCyte Inc (MXCT) Revenue 2024
MXCT reported a revenue (TTM) of $41.29 million for the quarter ending December 31, 2023, a -6.72% decline year-over-year.
MaxCyte Inc (MXCT) Net Income 2024
MXCT net income (TTM) was -$37.92 million for the quarter ending December 31, 2023, a -60.89% decrease year-over-year.
MaxCyte Inc (MXCT) Cash Flow 2024
MXCT recorded a free cash flow (TTM) of -$25.39 million for the quarter ending December 31, 2023, a +23.67% increase year-over-year.
MaxCyte Inc (MXCT) Earnings per Share 2024
MXCT earnings per share (TTM) was -$0.37 for the quarter ending December 31, 2023, a -60.87% decline year-over-year.
MaxCyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Mar 26 '24 |
Sale |
4.41 |
5,000 |
22,025 |
120,583 |
| Johnston John Joseph | Director |
Jan 26 '24 |
Option Exercise |
2.14 |
5,000 |
10,710 |
125,583 |
| Johnston John Joseph | Director |
Jan 26 '24 |
Sale |
5.12 |
5,000 |
25,585 |
120,583 |
| Johnston John Joseph | Director |
Dec 26 '23 |
Option Exercise |
2.14 |
5,000 |
10,710 |
125,583 |
| Johnston John Joseph | Director |
Dec 26 '23 |
Sale |
4.53 |
5,000 |
22,650 |
120,583 |
| Doerfler Douglas | President and CEO |
Dec 05 '23 |
Option Exercise |
0.04 |
99,442 |
3,978 |
432,639 |
| Doerfler Douglas | President and CEO |
Dec 05 '23 |
Sale |
5.17 |
99,442 |
514,115 |
333,197 |
| Doerfler Douglas | President and CEO |
Dec 04 '23 |
Option Exercise |
0.04 |
25,008 |
1,000 |
358,205 |
| Doerfler Douglas | President and CEO |
Dec 04 '23 |
Sale |
5.01 |
25,008 |
125,290 |
333,197 |
| Doerfler Douglas | President and CEO |
Dec 01 '23 |
Option Exercise |
0.04 |
20,200 |
808 |
353,397 |
About MaxCyte Inc
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
1.69%
0.48%
Cap:
|
Volume (24h):